Ma J, Song XQ. Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia. World J Psychiatry 2023; 13(10): 724-731 [PMID: 38058688 DOI: 10.5498/wjp.v13.i10.724]
Corresponding Author of This Article
Xue-Qin Song, PhD, Chief Physician, Department of Psychiatry, The First Affiliated of Zhengzhou University, No. 1 Jian Dong Road, Zhengzhou 450052, Henan Province, China. sxq907907@163.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Oct 19, 2023; 13(10): 724-731 Published online Oct 19, 2023. doi: 10.5498/wjp.v13.i10.724
Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia
Jing Ma, Xue-Qin Song
Jing Ma, First Department of Mood Disorders, The Second Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, Henan Province, China
Xue-Qin Song, Department of Psychiatry, The First Affiliated of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Ma J and Song XQ designed the study; Ma J wrote the manuscript; Ma J and Song XQ collected and analyzed the data; Ma J and Song XQ revised and reviewed the manuscript; All authors have read and approved the final manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of The First Affiliated of Zhengzhou University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Qin Song, PhD, Chief Physician, Department of Psychiatry, The First Affiliated of Zhengzhou University, No. 1 Jian Dong Road, Zhengzhou 450052, Henan Province, China. sxq907907@163.com
Received: June 6, 2023 Peer-review started: June 6, 2023 First decision: June 21, 2023 Revised: August 8, 2023 Accepted: August 15, 2023 Article in press: August 15, 2023 Published online: October 19, 2023 Processing time: 127 Days and 18 Hours
Core Tip
Core Tip: The highlights of this study are as follows. First, individuals with schizophrenia have imbalanced intestinal microbiota compared to healthy individuals. Second, patients with schizophrenia exhibit cognitive impairments in various areas such as attention, memory, social cognition, and executive function. Additionally, specific microbial groups such as Actinomycetes, Bacteroides, and Proteobacteria have shown a positive correlation with cognitive function in patients with schizophrenia. Furthermore, there is a close relationship between metabolic imbalance of intestinal flora and cognitive impairment in individuals with schizophrenia. Lastly, further clinical trials are necessary to gather more data and insights for the development of effective treatments for schizophrenia.
